2016 Call for Presentations

AATOD is no longer accepting submissions.

2016 Call for Presentation Brochure PDF

We are accepting application that will:

  • Address the issues and challenges of medication assisted treatment for opioid dependence in the context of improved access to care
  • Identify innovative strategies to expand and enhance the skills and the role of the behavioral healthcare workforce providing treatment
  •  Contribute to the adoption of evidence-based practices within opioid treatment
  • Build effective partnerships among and between organizations in developing new collaborative treatment models and recovery support services

Conference Objectives:

  • To present the latest evidence relevant to the field and critically evaluate the implications for patients, clinicians, administrators, and policy makers
  • To disseminate evaluation and treatment techniques to better serve patients and providers, improve program development and administration, and enhance patient outcomes
  • To develop strategies to assist healthcare partnerships and collaborations by advancing their understanding of medication assisted treatment as a crucial element to community wellness in an era of healthcare reform
  • To improve the collaboration between opioid treatment programs and community partners in response to the heightened risks associated with the use of opioids
  • To formulate methods to promote, support, facilitate, and integrate medication assisted treatment into the judicial and penal systems, government, and social service organizations
  • To discuss the magnitude and impact of prescription opioids on the healthcare system and Opioid Treatment Programs



Opioid Abuse as a Public Health Crisis

  • Prevalence of Non-Medical Use of Prescription Opioids
  • Factors Contributing to Over- and Under-Prescribing Opioids in the Healthcare System
  • Assessing Opioid Misuse Risk & Monitoring for Harm
  •  Overdose Risk Assessment and Overdose Prevention

Behavioral Health: Diagnosis and Treatment

  • Evidence Based Individual and Group Therapy Interventions
  • Addressing Co-occurring Physical and Psychiatric Disorders in the OTP
  • Harm Reduction Approaches
  •  Motivational Interviewing & Motivational Enhancement Therapy
  •  DSM-5 Diagnostic Assessments, Case Formulation, and Treatment Planning
  • Strengths Based Treatment Planning


  • Medication Assisted Treatment (MAT): How Far Have We Come?
  • Outcome Studies: Methadone, Buprenorphine, Naltrexone
  •  Naltrexone: Efficacy, Utilization, Induction Techniques, Barriers to Prescribing
  • Risk/Benefit Analysis of Benzodiazepines
  •  Genetics and/or Neuroscience of Addiction Medicine

OTP Best Practices

  • Policies, Role of Supervisors & Counselors, Behavioral Management, Crisis Intervention, Medication Exclusions
  • Using Technology to Improve the OTP and Patient Outcomes
  •  Concurrent Illicit Drug Use in OTPs
  •  Promoting Staff Wellness

Patient Care

  •  Countering Stigma in MAT
  • Peer Support
  •  Engaging Family Members in Treatment
  •  MAT for Specific Groups: Women, Ethnic Minorities, LGBTQ
  •  Health Coaching
  •  Tobacco Cessation
  •  Cannabinoid Use

Community Partners

  • Building Partnerships: Criminal Justice System & Law Enforcement
  •  Outcomes and Utilization Data from Drug Courts
  • Effective Models in Working with Drug Courts
  • Effective Strategies for Educating Community Partners about MAT
  • Community Outreach and Coordination of Care
  • Effective Consultation Strategies for Prescribers Across Various Medical Disciplines

Public Policy/Regulatory Issues

  • Prescription Drug Monitoring Programs
  • Delivering MAT in Healthcare Reform: Basics and Beyond
  •  Early Impact of Health Care Reform on Patient Access
  •  Working with SOTAs and Other Regulators
  •  Diversion Control Strategies

Risk Issues

  •  Differential Decisions: Risk Issues and Safety Profiles of Various Opioid Medications
  • Risk Assessment and Monitoring Tools for Opioid Prescription Use
  • Overdose Management, Overdose Risk Assessment, and Overdose Prevention

Workshop presentations are 90 minutes in length. Workshop presentations may include up to three speakers. In some instances, the Workshop Committee may make suggestions to combine presentations similar in content into one workshop.

If submitting for a poster, please note that the Poster Author Sessions on Monday, October 31st from 7:30 a.m.–8:45 a.m. and from 3:00 p.m.–4:00 p.m. are mandatory and all authors must be present at the Poster Board in the Grand Ballroom to discuss the poster and answer questions.


Share This